CVM-1118 is primarily investigated for its potential in cancer therapy. It has shown promise in inhibiting the growth and proliferation of various cancer cells, particularly in cases where traditional treatments have limited efficacy. The compound is being studied for its ability to target specific pathways involved in tumor progression, making it a candidate for combination therapies with existing chemotherapeutic agents. Additionally, CVM-1118 is being explored for its role in reducing metastasis, which could significantly improve outcomes for patients with advanced-stage cancers. Research is ongoing to determine its safety, optimal dosing, and effectiveness in clinical settings.